TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620164

Intervention type: OTHER
Group type: OTHER
Intervention: Psychophysical measurements of 3D perception
Description: 3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.

Intervention type: OTHER
Group type: OTHER
Intervention: Psychophysical measurements of 3D perception
Description: 3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.

Intervention type: OTHER
Group type: OTHER
Intervention: Psychophysical measurements of 3D perception
Description: 3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
Study: NCT02760771

Intervention type: OTHER
Intervention: with BAV
Description: balloon dilation of the aortic valve prior to implantation of the THV

Intervention type: OTHER
Intervention: without BAV
Description: no balloon dilation of the aortic valve prior to implantation of the THV
Study: NCT01069861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildanefil
Description: Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
Study: NCT00504504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC)
Description: 375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
Study: NCT01691885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: 100mcg Once daily
Study: NCT01052051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Calcium carbonate 1500mg / daily
Study: NCT05548166

Intervention type: OTHER
Intervention: Interview and scale development
Description: Interview and scale development

Intervention type: OTHER
Intervention: Interview and scale development
Description: Interview and scale development

Intervention type: OTHER
Intervention: Interview and scale development
Description: Interview and scale development
Study: NCT01691885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Furoate
Description: 100mcg Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: 25mcg Once daily
Study: NCT03389867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract
Study: NCT01691885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vilanterol
Description: 25mcg Once daily
Study: NCT03581539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverses Abdominis Plane (TAP) block
Description: TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum (QL) block
Description: QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Infiltration using Exparel
Description: SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
Study: NCT02568098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Description: Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
Study: NCT00766272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
Study: NCT02070081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery or sleeve surgery
Study: NCT00846911

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
Study: NCT02568098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Description: Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Description: Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ and DHA-PQP and PQ
Description: Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
Study: NCT03867929

Intervention type: OTHER
Intervention: 25-Hydroxy vitamin D
Description: 27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
Study: NCT01711944

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem-Solving Skills Training
Description: 8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
Study: NCT04481750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension
Study: NCT02568098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ and DHA-PQP and PQ
Description: Regimen 5: PQ; Regimen 7: DHA-PQP and PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PQP
Description: Regimen 6: DHA-PQP
Study: NCT00037817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: assigned dose level on day 4 and day 10 of each 34 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: assigned dose level on day 4 and day 10 of each 34 day cycle
Study: NCT01711944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Skills Training
Description: 8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
Study: NCT01628718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Disclosure (AD)
Description: Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
Study: NCT00037817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: assigned dose level on day 4 and day 10 of each 34 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: assigned dose level on day 4 and day 10 of each 34 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: assigned dose level on day 4 and day 10 of each 34 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: assigned dose level on day 4 and day 10 of each 34 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400mg PO BID on days 4 through 34 of each cycle
Study: NCT02976480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No irrigation
Description: A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
Study: NCT03829943

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Blood will be drawn for Vitamin D level

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Blood will be drawn for Vitamin D level
Study: NCT01944566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial transplant
Description: Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
Study: NCT04621214

Intervention type: DEVICE
Intervention: Audio-Visual Triage System (AVT)
Description: Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication

Intervention type: DEVICE
Intervention: Audio-Visual Triage System (AVT)
Description: Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
Study: NCT01882010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline solution daily subcutaneous injection 56 days

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Controls
Description: Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
Study: NCT03804567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oldpain2go®
Description: This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine low back pain management
Description: Standard low back persistent physiotherapy management as recommended by national guidelines.
Study: NCT01620515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207 2.5 mg
Description: A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207 15 mg
Description: A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
Study: NCT01129089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement
Description: Lipid-based nutrient supplement for pregnant and lactating women

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement
Description: Lipid-based nutrient supplement for infant and young children

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powder
Description: Micronutrient powder for infant and young children
Study: NCT01628718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy, cognitive version only (CPT-C)
Description: Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery.
Study: NCT01511549

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT04481750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186-matching placebo
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186-matching placebo
Description: Solution or suspension
Study: NCT01511549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:injection~Route of administration: intra-articular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:injection~Route of administration: intra-articular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT00536640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg per os, given daily until tumor progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg i.v. on day 1 (three-week cycle) until tumor progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15mg/kg i.v. on day 1 (three-week cycle) until tumor progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
Study: NCT04481750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186-matching placebo
Description: Solution or suspension
Study: NCT00742365

Intervention type: DEVICE
Intervention: Bright light
Description: One hour of exposure to bright light daily upon awakening for 6 weeks.

Intervention type: DEVICE
Intervention: Red light placebo
Description: One hour of exposure to red light.
Study: NCT04962841

Intervention type: OTHER
Intervention: Nutraceuticals
Description: To observe the effect on cognitive and physical impairment.
Study: NCT03525184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional protein and multi-nutrient beverage
Description: During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
Study: NCT04481750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186-matching placebo
Description: Solution or suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186-matching placebo
Description: Solution or suspension
Study: NCT04079062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONO-4685
Description: Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by intravenous continuous infusion at the designated speed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH, ONO-4685
Description: Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH, placebo
Description: Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
Study: NCT02502669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 23.5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 33.5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT03891004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular Skin Closure
Description: We will only close the subcuticular layer with suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesives
Description: No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
Study: NCT02027467

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: StemAlive®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (For StemAlive®)
Study: NCT01418131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal tacrolimus
Description: Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo